Cargando…

Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine

BACKGROUND: Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in older adults and adults with comorbidities. An effective vaccine is needed. An investigational bivalent prefusion F vaccine (RSVpreF) was assessed in healthy adults. METHODS: This phase 1/2 study randomized a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falsey, Ann R, Walsh, Edward E, Scott, Daniel A, Gurtman, Alejandra, Zareba, Agnieszka, Jansen, Kathrin U, Gruber, William C, Dormitzer, Philip R, Swanson, Kena A, Jiang, Qin, Gomme, Emily, Cooper, David, Schmoele-Thoma, Beate
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200152/ https://www.ncbi.nlm.nih.gov/pubmed/34931667 http://dx.doi.org/10.1093/infdis/jiab611

Ejemplares similares

A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine
por: Walsh, Edward E, et al.
Publicado: (2021)

A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults
por: Baber, James, et al.
Publicado: (2022)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine
por: Peterson, James T, et al.
Publicado: (2021)

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023)

2781. Statistical Modeling to Predict Maternal RSV Vaccine Efficacy from Neutralizing Titers
por: Cai, Bing, et al.
Publicado: (2019)

1941. Coadministration of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine With Influenza Vaccine in Older Adults
por: Baber, James A, et al.
Publicado: (2023)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

1634. Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR)
por: Walsh, Edward E, et al.
Publicado: (2023)

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
por: Walsh, Edward E., et al.
Publicado: (2020)

Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
por: Bouzya, Badiaa, et al.
Publicado: (2023)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

1098 The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions
por: Schmoele-Thoma, Beate, et al.
Publicado: (2014)

1630. Clinical Profile of Acute Respiratory Illness (ARI) Events in the Phase 3 Trial The RSV Vaccine Efficacy Study iN Older Adults Immunized against RSV Disease (RENOIR)
por: Marc, Gonzalo Pérez, et al.
Publicado: (2023)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
por: Hu, Yuemei, et al.
Publicado: (2019)

Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
por: Rainho-Tomko, Jennifer N., et al.
Publicado: (2022)

An open-label randomized clinical trial of prophylactic paracetamol coadministered with 7-valent pneumococcal conjugate vaccine and hexavalent diphtheria toxoid, tetanus toxoid, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b vaccine
por: Rose, Markus A, et al.
Publicado: (2013)

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
por: Baxter, Roger, et al.
Publicado: (2015)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial
por: Bebia, Zourab, et al.
Publicado: (2023)

Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)
por: Creech, C Buddy, et al.
Publicado: (2019)

Gamma Irradiation-Inactivated Respiratory Syncytial Virus Vaccine Provides Protection but Exacerbates Pulmonary Inflammation by Switching from Prefusion to Postfusion F Protein
por: Chen, Fengjia, et al.
Publicado: (2023)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer
por: Boeckh, Michael J, et al.
Publicado: (2020)

Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness
por: Mazur, Natalie I, et al.
Publicado: (2019)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence
por: Chilson, Erica, et al.
Publicado: (2020)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
por: Thompson, Allison R., et al.
Publicado: (2018)

91. Establishing Proof of Concept for a Bivalent RSVpreF Subunit Vaccine for Maternal Immunization
por: Simões, Eric A F, et al.
Publicado: (2022)

Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein
por: Cimica, Velasco, et al.
Publicado: (2016)

2139. Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults
por: Chandler, Reynaldo, et al.
Publicado: (2022)

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age
por: Díez-Domingo, Javier, et al.
Publicado: (2022)

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
por: Falloon, Judith, et al.
Publicado: (2017)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years: An open-label trial
por: Shiramoto, Masanari, et al.
Publicado: (2014)

Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection
por: Acosta, Camilo J, et al.
Publicado: (2022)

Effects of Prior Influenza Exposure on Immunogenicity of Influenza Vaccine
por: Cao, Jia-Qian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hnmkq7eb820cc0mm4pafaoftu6